Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2673 - Predictive factors for T790M mutation in plasma in patients after progression to 1st line tyrosine-kinase inhibitor (TKI) with or without subsequent lines of TKI or chemotherapy for metastatic epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)


08 Oct 2016


Poster Display


Kin-Sang Lau


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


K. Lau, T. So, T. Choy, D.K. Leung, K. Lam, P.Y.P. Ho, W. Chan, L. Wong, S. Chan, F. Chan, R.P. Tse, C. Choi, T. Lam, D.W. Kwong, A. Lee, T. Leung, V.H. Lee

Author affiliations

  • Department Of Clinical Oncology, The University of Hong Kong, Nil - Hong Kong/HK


Abstract 2673


Liquid re-biopsy has become an acceptable alternative to tumor re-biopsy to identify acquired T790M mutation after tyrosine-kinase inhibitors with or without subsequent chemotherapy for metastatic EGFR-mutated NSCLC. We prospectively investigated if there were any predictors for development of acquired T790M mutation in plasma DNA.


Patients with tumour-biopsy proven activating EGFR mutations who received 1st line TKI with or without subsequent lines of TKI and/or chemotherapy after failure to 1st line TKI were prospectively recruited. Blood (10ml ETDA) was taken for plasma DNA for the detection of T790M mutation at the time of progressive disease to TKI with or without subsequent TKI/chemotherapy. Univariable and multivariable logistic regression was performed for clinical and molecular predictors for presence of T790M mutation.


68 patients received TKI alone with or without further TKI/chemotherapy before liquid re-biopsy at the time of progressive disease. 19 (51.4%) patients with initial exon 19 deletion versus 8 (25.8%) patients with initial exon 21 mutation developed T790M on liquid re-biopsy (p = 0.032). Univariable analysis showed that age ≥75 years (OR 4.15, 95% CI 1.06-16.21, p = 0.041), ≥2 sites of distant metastases before 1st line TKI (OR 13.51, 95% CI 1.65-111.11 p = 0.015) and exon 19 deletion (vs. exon 21 mutations) (OR 3.04, 95% CI 1.08-8.51, p = 0.035) were significant predictive factors, while multivariable analysis showed that ≥2 sites of distant metastases (OR 13.70, 95% CI 1.64-111.11, p = 0.001) and exon 19 deletion (OR 3.09, 95% CI 1.03-9.29, p = 0.039) were independent predictive factors of development of T790M mutation. Use of chemotherapy and use of more than 1 line of TKI were not predictors.


Targeted patient subgroups were identified for the development of T790M mutation after 1st line TKI and/or subsequent TKI/chemotherapy, which were important to guide subsequent management.

Clinical trial identification

Legal entity responsible for the study

Department of Clinical Oncology, The University of Hong Kong




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings